T2 Biosystems
101 Hartwell Avenue
Lexington, MA 02421
Phone: 781-457-1200
Fax: 781-357-3080

T2Biothreat Panel

Detection of biothreat pathogens in 3-5 hours— direct from whole blood: The T2Biothreat® Panel, which runs on the T2Dx® Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously detects six biothreat pathogens identified as threats by the U.S. Government, including B. anthracisF. tularensisB. mallei , B. pseudomalleiY. pestis, and R. prowazekii.

Clinical Trial: The T2Biothreat clinical trial for evaluating the Panel was initiated in December 2021, and will support a submission to the U.S. Food and Drug Administration (FDA).

“We are pleased to initiate the clinical trial for our novel T2Biothreat Panel as we continue to advance our product development strategy ahead of schedule. We are confident that the results will highlight the versatility of our technology, including our T2Dx Instrument, and its unique ability to help protect our nation in the face of a biothreat incident. We thank BARDA for its continued support and collaboration as we expand our portfolio of blood culture independent rapid diagnostic products.” — John Sperzel, Chief Executive Officer

T2MR® Technology: The T2Biothreat Panel utilizes the same T2MR® Technology and T2Dx Instrument as the T2Bacteria® and T2Candida® Panels – the first and only FDA-cleared and CE-marked panels for detection of sepsis-causing bloodstream infections direct from a patient’s blood sample, without requiring blood culture results.

Contact us to learn more about the T2Biothreat Panel.

T2 Biosystems has done what many said could not be done. Its T2MR technology generates accurate, rapid results using direct sample analysis of whole blood without relying on blood culture. The T2Candida Panel represents how T2MR is the next breakthrough in medical diagnostics, and it has significant potential to save lives and reduce healthcare costs.

Michael Pfaller, MD, Former Chief Medical Officer, T2 Biosystems, Lexington, MA; Professor Emeritus, University of Iowa College of Medicine & College of Public Health, Iowa City, IA

What we need is a test that is 90% sensitive and 90% specific. That’s the test that makes a difference. If you’re at 90/90 then the negative predictive value is exceptional in virtually every population you use it in…that’s really clinically the most meaningful performance that we can achieve.

Cornelius J. Clancy, MD, Associate Professor of Medicine, Director, Mycology Program, University of Pittsburgh, Pittsburgh, PA

The ability to determine the presence or absence of Candida within hours – compared to days – is paradigm changing for patients at risk for these infections.

Eleftherios Mylonakis, MD, PhD, FIDSA, Chief, Division of Infectious Diseases, Rhode Island Hospital and The Miriam Hospital and Dean's Professor of Medical Science, Alpert Medical School of Brown University, Providence, RI

We believe combining our collective expertise with T2 Biosystems' proprietary T2MR platform may enable us to develop a fully differentiated diagnostic panel for the detection of Lyme disease, an area of critical need where delays in providing appropriate treatment to patients can result in significant morbidity and unnecessary costs.

Akiko Tanaka, President and CEO of Canon U.S. Life Sciences